A patient walks into an ophthalmology practice for a LASIK consultation. The procedure costs $4,500 per eye. The patient doesn't have $9,000 sitting in a checking account, so the practice hands them a CareCredit application and Synchrony Financial approves a credit line with a deferred-interest promotion the patient will almost certainly misunderstand. The patient leaves the office with financing at 32.99% APR accruing in the background. That's one transaction. Run it across more than 285,000 provider locations and a substantial portion of Synchrony's $104.7 billion loan receivables portfolio, and that's the consumer finance stack embedded in American elective healthcare.

We wrote recently about $4 billion in ophthalmology practice value sitting in transition with nobody on the other side. Practice owners trying to exit, PE platforms pulling back, hospitals paying hard-asset prices with no goodwill, and 75% of practice sales failing before they close. That's the supply-side story, and the asset class has a buyer problem.

The story that piece didn't cover is the other side of the same machine. While PE operators extract margin from the physician side of the ophthalmology transaction, consumer finance vendors extract margin from the patient side. Both extraction structures run in parallel inside the same industry, both compound over time, and both are structurally invisible to the people paying for them.

How Consumer Finance Extracts Margin from Ophthalmology Patients

CareCredit is the dominant patient financing product in elective healthcare. Synchrony Financial's 2024 10-K reported $182.2 billion in total purchase volume and 71.5 million active accounts across the company's five sales platforms at year-end. Health & Wellness, the segment that houses CareCredit, grew purchase volume 10.4% in Q4 2024 driven by Pet, Dental, and Cosmetic. The CareCredit provider network exceeded 285,000 locations by year-end 2024. The standard purchase APR on new CareCredit accounts sits at 32.99% effective May 30, 2024, with a penalty APR of 39.99%. Deferred-interest promotions advertise 0% financing for 6, 12, 18, or 24 months, and if the balance isn't paid in full by the end of the promotional period, all accrued interest gets billed retroactively at the standard rate.

The Consumer Financial Protection Bureau's May 2023 report on medical credit cards and financing plans found that consumers paid $1 billion in deferred interest on approximately $23 billion in healthcare card purchases between 2018 and 2020. The average cost to consumers who triggered back-interest was approximately 23% of the original purchase amount. The CFPB's March 2022 report on medical debt found $88 billion in medical debt on credit reports, with 43 million consumer reports affected and medical debt accounting for 58% of all collections tradelines. The money moves cleanly from patient wallets to lender balance sheets, and until recently the full scope of that transfer wasn't even publicly measurable.

The CFPB finalized a rule on January 7, 2025 that would have removed approximately $49 billion of medical debt from 15 million Americans' credit reports. In July 2025, the Eastern District of Texas vacated the rule in Cornerstone Credit Union League v. CFPB, nullifying it nationwide. The regulatory overhang reduced and the extraction continued. The dynamic extends beyond CareCredit. Wells Fargo Health Advantage runs a similar product at a materially lower APR but with a smaller footprint. Alphaeon Credit, operated through Comenity Capital Bank and now Bread Financial, targets ophthalmology, dermatology, plastic surgery, dental, and veterinary specifically, with credit lines up to $25,000 and a minimum promotional purchase of $250. Specialty lenders have been rolling into specialty medicine for a decade because the margin on elective cash-pay procedures is where consumer finance finds its highest yields.

Why This Structure Compounds the PE Extraction Problem in Ophthalmology

The argument for PE in ophthalmology has always been that scale delivers operational efficiency through shared administration, centralized billing, better insurance contracting, and consolidated supply chain. The EyeCare Partners platform, which scaled to approximately 300 ophthalmologists and 700 optometrists across 19 states before executing a distressed debt exchange in April 2024, was built on that thesis. What the thesis leaves out is that PE platforms don't just extract margin from the physician side of the ophthalmology transaction. They also centralize the patient financing relationship in ways that a standalone practice cannot.

A solo practice owner negotiates directly with CareCredit or Wells Fargo on standard terms, which means the patient financing economics flow through the practice at arm's length. A PE platform operating hundreds of locations negotiates master agreements with patient financing vendors at volumes that produce favorable referral economics, rebates, and in some cases revenue-sharing structures that get buried in the platform's financial statements rather than returned to the patient as lower rates. The same patient at the same practice pays meaningfully different economics depending on whether the practice is independent or rolled into a platform, and the difference doesn't show up on the patient's invoice.

JAMA Surgery published a study in November 2025 from Hernandez and colleagues finding that 37.9% of surgical patients experienced financial hardship, with surgical procedures driving a 5.4 percentage point increase in hardship probability relative to non-surgical care. The financial hardship rate for uninsured patients was 23.7 percentage points higher than for insured patients. The study covered all surgery, not ophthalmology specifically, but the pattern is consistent with what CFPB data shows about deferred-interest triggers in elective healthcare. The US LASIK market was approximately $1.48 billion in 2023 according to Market Scope, with out-of-pocket costs ranging from $1,500 to $5,000 per eye. Premium intraocular lenses for cataract surgery run $2,000 to $4,500 per eye above Medicare's standard reimbursement, governed by CMS Rulings 05-01 and 1536R. The combined US cash-pay elective ophthalmology and aesthetics TAM is somewhere between $10 billion and $15 billion, growing at double-digit rates, and every dollar of that total runs through a financing layer that captures a percentage of it before the patient ever walks out of the exam room.

The Structural Answer Isn't Eliminating Ophthalmology Patient Financing

Patient financing genuinely expands access. The CFPB's own 2023 report acknowledged that the majority of consumers using medical credit cards during promotional periods pay in full without triggering back-interest. For patients who would otherwise forgo elective procedures or turn to higher-rate general-purpose credit cards, specialty medical financing is often the best available option, and the practices that offer it responsibly are delivering care that wouldn't otherwise happen.

The structural problem sits somewhere else, specifically that the financing layer, the PE platform layer, and the physician employment layer are all optimized for extraction simultaneously, without any counterweight on the patient side beyond regulatory action that has historically lagged the market by a decade. When the same capital allocator owns the practice, the patient financing company, and the surgical supply vendor, the integrated structure can extract at every stage of the patient's journey, and the patient has no meaningful way to shop around inside a single appointment.

Patient Capital, the specialty lending business inside Leon Capital Group's $10 billion AUM family holding company, represents a different structural posture. Leon Capital's healthcare stack includes Physician Directed Partners, Advanced MedAesthetic Partners, and CityVet, which creates vertical integration that can capture both the physician side and the patient side of the transaction. Whether that integration ends up optimizing for extraction or for patient outcomes depends entirely on how the individual operator chooses to run it. The structure itself is neutral. The incentives embedded in it are not.

What a Different Structural Posture Looks Like in Ophthalmology

For practice owners evaluating succession options, the financing layer matters because a PE acquirer will typically renegotiate financing relationships in ways that prioritize platform economics over practice-level patient outcomes. A permanent-hold acquirer operates with different incentives, specifically because the hold period doesn't carry a forced exit that requires maximizing extractable margin over a 5-to-7 year window. Patience becomes an economic posture rather than a compliance feature, and the patients who walk through the door in year 12 of a permanent hold pay different rates than the patients who walk through the door in year 4 of a PE platform approaching its secondary sale.

The $4 billion practice value problem and the consumer finance machine running inside elective healthcare aren't two different stories. They're two ends of the same structure, running on the same asset class, with the same structural incentives to extract margin wherever it's available. Understanding the full shape of that machine is the first step toward building something that runs differently, and the people most qualified to build it are the physicians who have spent a career watching both ends of it squeeze the same patients they've been treating for 20 years.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com